The yeast infection diagnostics market size is projected to be worth US$ 417.7 Million in 2023. The market is likely to surpass US$ 711.4 Million by 2033 at a CAGR of 5.5% during the forecast period. Growing yeast infection incidences is aiding the market growth. When the vagina is infected with Candida, it is referred to as a yeast infection. Candida is a kind of yeast. Candidiasis is most typically seen as a secondary illness in immunocompromised people. These are frequent dwellers in the mouth cavity, gastrointestinal tract, vagina, penis, and other areas. They only become pathogenic when favorable conditions exist. It can affect the mouth, vagina, penis, and other areas of the body. Antibiotic use is frequently linked to candidiasis. Cancer cytotoxic treatment can produce Candida albicans fungemia, which develops from fungal translocation across damaged mucosal barriers. Candidiasis is more common in old age and infants, according to NIH: StatPearls 2023. Yeast infection affects around 37% of newly born newborns in the United States.
Other Drivers Propelling the Demand for Yeast Infection Diagnostics Market include:
Challenges for Companies /Manufacturers in the Yeast Infection Diagnostics Market:
Opportunities in the Yeast Infection Diagnostics Market Industry:
Latest Trends in the Yeast Infection Diagnostics Market:
| Attributes | Details |
|---|---|
| Yeast Infection Diagnostics Market Size (2023) | US$ 417.7 Million |
| Yeast Infection Diagnostics Market Projected Size (2033) | US$ 711.4 Million |
| Value CAGR (2023 to 2033) | 5.5% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
From 2012 to 2022, the global yeast infection diagnostics market experienced a CAGR of 4.4%, reaching a market size of US$ 417.7 Million in 2023.
From 2012 to 2022, the global yeast infection diagnostics market industry witnessed steady growth due to the increased prevalence of yeast infection. According to COVID-19, fungal infections can cause serious disease and death. COVID-19 with a fungal infection can coexist in some people. COVID-19 therapies, such as steroids and other medicines, can reduce the body's ability to fight fungus.
The creation of diagnostic kits has been facilitated by advances in genomic research and understanding of the genetic underpinnings of yeast specific biomarker.
Future Forecast for Yeast Infection Diagnostics Market Industry:
Looking ahead, the global Yeast Infection Diagnostics Market industry is expected to rise at a CAGR of 5.5% from 2023 to 2033. During the forecast period, the market size is expected to reach US$ 711.4 Million by 2033.
The yeast infection diagnostics market industry is expected to continue its growth trajectory from 2023 to 2033. Next generation sequencing has made diagnosis of causal species easy, with intervention of other detection techniques and artificial intelligence. Diagnosis process is prone to become easy, rapid and in small point-of-care testing.
Early identification and diagnosis of yeast infection improves patient health outcomes significantly. Yeast infection diagnostics offer the ability to detect infection and type of causal agent in early-stage of infection, allowing for earlier intervention and better survival rates. The emphasis on early diagnosis is anticipated to drive future demand for yeast infection diagnostic market.
| Country | The United States |
|---|---|
| Market Size (US$ Million) by End of Forecast Period (2033) | US$ 204.9 Million |
| CAGR % 2023 to End of Forecast (2033) | 4.5% |
The Yeast Infection Diagnostics Market industry in the United States is expected to reach a market size of US$ 204.9 Million by 2033, expanding at a CAGR of 4.5%. Vaginal candidiasis is the most prevalent among all the yeast infections, according to the Centers for Disease Control and Prevention 2022. It is considered to be the second most prevalent kind of vaginal infection in the USA, following bacterial vaginal infections. Annually, around 1.4 million outpatient consultations for vaginal candidiasis are made.
| Country | The United Kingdom |
|---|---|
| Market Size (US$ Million) by End of Forecast Period (2033) | US$ 51.6 million |
| CAGR % 2023 to End of Forecast (2033) | 3.7% |
The yeast infection diagnostics market industry in the United Kingdom is expected to reach a market value of US$ 51.6 Million, expanding at a CAGR of 3.7% during the forecast period. According to the 2013 Health Technology Assessment, Candida albicans represented 61% of all Invasive fungal disease. According to an article provided by Public Health England 2021, the overall incidence of Candidaemia in England was 3.5 every 100,000 inhabitants in 2020, a modest rise from 2019 (3.1 per 100,000), with older people having the most severe prevalence of Candidaemia.
The rise in frequency between 2019 to 2020 might be attributed to a significant rise in the number of patients referred to intensive care units (ICUs) in the year 2020 as an outcome of the COVID-19 pandemic. Patients in ICUs are more likely to develop Candidaemia because the environment permits the opportunistic pathogen to grow invasive, and multiple risk factors underlying Candidaemia overlap with features of ICU patients. The present epidemiologic demographics of IFD in UK critical care units is described in the aforementioned paragraph.
| Country | China |
|---|---|
| Market Size (US$ Million) by End of Forecast Period (2033) | US$ 64.8 million |
| CAGR % 2023 to End of Forecast (2033) | 6.8% |
The yeast infection diagnostics market industry in China is anticipated to reach a market size of US$ 64.8 million, moving at a CAGR of 6.8% during the forecast period. The yeast infection diagnostics market industry in China is expected to grow prominently due to the increasing commercial intervention in production of rapid diagnostic kits and real time PCR kits. As per The Lancet Infectious Diseases today 2018, Chinese, women are the world’s most numerous sufferers of thrush at 29.1 million.
| Country | Japan |
|---|---|
| Market Size (US$ Million) by End of Forecast Period (2033) | US$ 48.2 million |
| CAGR % 2023 to End of Forecast (2033) | 6.4% |
The yeast infection diagnostics market industry in Japan is estimated to reach a market size of US$ 48.2 million by 2033, thriving at a CAGR of 6.4%. When pre-reproductive and reproductive population are nearly comparable in quantity or proportion, and post-reproductive population have very few, bell-shaped age pyramids arise. Japanese demography reflects a curve with a bell shape, indicating that Japan has a larger elderly population. According to Geriatrics (Basel) 2020, there is an elevated prevalence of oral Candidiasis diagnosis in reliant Japanese elderly people. When contrasted with independent older adults, dependent seniors might be more prone to oral Candida albicans infection. As a result, Japan has emerged as a key market for yeast infection diagnostics.
| Country | South Korea |
|---|---|
| Market Size (US$ Million) by End of Forecast Period (2033) | US$ 5.1 Million |
| CAGR % 2023 to End of Forecast (2033) | 8.2% |
The yeast infection diagnostics market industry in South Korea is expected to reach a market size of US$ 5.1 million, expanding at a CAGR of 8.2% during the forecast period. South Korea is well-known for its technology breakthroughs and healthcare innovation. The country's strong emphasis on research and development, along with a favorable regulatory framework, leads to the growth of the yeast infection diagnostics market by allowing the development and commercialization of improved diagnostic technologies.
Principal Consultant
The test strips are predominant in yeast infection diagnostics market industry with a market share of 60.2% in 2022. Antifungal susceptibility testing (AFST) is currently frequently utilized and recommended in the treatment of patients suffering from persistent fungal infections like candidiasis and aspergillosis. The average vaginal pH ranges from 3.8 to 5.0. During a vaginal infection, the pH rises to 5.0-5.5 or 6.0-7.5, and vulvovaginal candidiasis is responsible for 20% to 25% of all vaginitis cases. The test strip is used to detect changes in vaginal pH; it is a tiny, paper-like strip that is put into the vagina for a few seconds before being compared to a color chart to ascertain the pH level.
The vaginal pH Test constitutes 61.9% market share globally in 2022. Vaginal pH strip is more prominently used as it is easy to use by the patients. The strip is cost effective with comparison to the other diagnostic kits. It is more convenient and non-invasive method for initial screening of yeast infection.
The Hospitals are dominating the yeast infection diagnostics market with the market share of 39.2% in 2022. A hospital is able to cut expenses by offering a complete range of services to patients. Doctors can utilize a variety of diagnostic tests to determine the source of a patient's symptoms. A commitment to provide high-quality care at a reasonable cost. A hospital can assist in identifying potential issues early on, before they become more serious. It enables rapid intervention and therapy, which improves the results for patients.
The market for yeast infection diagnostics is very competitive, with numerous businesses vying for market supremacy. In order to remain a step ahead of the competition in a scenario like this, major players have to implement smart strategies.
Key Strategies Used by the Participants
Key players focus on developing and introducing innovative products to address unmet needs in the market. They invest in research and development to improve existing formulations, delivery systems, and enhance the efficacy and safety of the products
Key players often form strategic partnerships and collaborations with other companies, research institutes, or healthcare organizations, these partnerships allow for knowledge sharing, joint research and development efforts, and access to complementary technologies or expertise.
Key players strive to expand their presence in different geographic regions to tap into new markets and reach a wider customer base. They may establish subsidiaries, distribution networks. Or strategic alliances in various countries to strengthen their market position.
Companies in the market may engage in mergers or acquisitions to consolidate their product portfolio, acquire new technologies, these strategic moves allow companies to enter new market segments, gain access to novel products or intellectual property, and achieve synergies in terms of research, manufacturing, or distributions.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Key Developments in the Yeast Infection Diagnostics Market:
An increase in technological advancements drives the demand.
The rapid and reliable detection of a small number of infectious agents drives sales.
The market expands at a CAGR of 5.5% from 2023 to 2033.
The increase in commercial intervention in the production of rapid diagnostic kits raises the demand in China.
China is likely to expand at a CAGR of 6.8% from 2023 to 2033.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Value Added Insights 4.1. Product Adoption / Usage Analysis 4.2. Recent Product Approvals/Launches 4.3. Regulatory Landscape 4.4. Statistics of Yeast infection & Treatment Procedures 4.5. PESTEL Analysis 4.6. Porter’s Analysis 4.7. Unmet Needs for Diagnostic Kits 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global Healthcare Expenditure Outlook 5.1.2. Global Medical Device Outlook 5.1.3. Global Life Expectancy Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Key Player’s Historic Growth 5.2.2. Growing Awareness about Cancer Diseases 5.2.3. Favourable Government Regulations 5.2.4. Rising Demand for Minimally Invasive Procedures 5.2.5. Technological Advancement in the Devices 5.2.6. Increasing Prevalence of Yeast Infection 5.3. Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. Global Market Volume (in Units) Analysis 2012 to 2022 and Forecast, 2023 to 2033 6.1. Historical Volume (in Units) Analysis, 2012 to 2022 6.2. Current and Future Volume (in Units) Projections, 2023 to 2033 6.2.1. Y-o-Y Growth Trend Analysis 7. Global Market - Pricing Analysis 7.1. Regional Pricing Analysis By Product 7.2. Pricing Break-up 7.2.1. Manufacturer Level Pricing 7.2.2. Distributor Level Pricing 7.3. Global Average Pricing Analysis Benchmark 7.4. Pricing Assumptions 8. Global Market Demand (in Value or Size in US$ Mn) Analysis 2012 to 2022 and Forecast, 2023 to 2033 8.1. Historical Market Value (US$ Million) Analysis, 2012 to 2022 8.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033 8.2.1. Y-o-Y Growth Trend Analysis 8.2.2. Absolute $ Opportunity Analysis 9. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Product 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Product, 2012 to 2022 9.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Product, 2023 to 2033 9.3.1. Strips 9.3.2. Cassettes 9.3.3. Panel Test 9.4. Market Attractiveness Analysis By Product 10. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Test Type 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis By Test Type, 2012 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Test Type, 2023 to 2033 10.3.1. Vaginal pH Test 10.3.2. Nucleic Acid Amplification Testing (NAAT) 10.3.3. Microbiome Test 10.4. Market Attractiveness Analysis By Test Type 11. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Body Part 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) Analysis By Body Part, 2012 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Body Part, 2023 to 2033 11.3.1. Vagina 11.3.2. Penis 11.3.3. Mouth 11.3.4. Nail 11.3.5. Skin folds 11.4. Market Attractiveness Analysis By Body Part 12. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Indication 12.1. Introduction / Key Findings 12.2. Historical Market Size (US$ Million) Analysis By Indication, 2012 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2023 to 2033 12.3.1. Vulvovaginal Candidiasis 12.3.2. Trichomoniasis 12.3.3. Chlamydia 12.3.4. Gonorrhea 12.3.5. Bacterial Vaginosis 12.4. Market Attractiveness Analysis By Indication 13. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By End User 13.1. Introduction / Key Findings 13.2. Historical Market Size (US$ Million) Analysis By End User, 2012 to 2022 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2023 to 2033 13.3.1. Hospitals 13.3.2. Diagnostic Laboratories 13.3.3. Specialty Clinics 13.3.4. Homecare Settings 13.4. Market Attractiveness Analysis By End User 14. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, by Region 14.1. Introduction 14.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Region, 2012 to 2022 14.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Region, 2023 to 2033 14.3.1. North America 14.3.2. Latin America 14.3.3. Europe 14.3.4. South Asia 14.3.5. East Asia 14.3.6. Oceania 14.3.7. Middle East and Africa (MEA) 14.4. Market Attractiveness Analysis By Region 15. North America Market Analysis 2012 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2012 to 2022 15.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. USA 15.3.1.2. Canada 15.3.2. By Product 15.3.3. By Test Type 15.3.4. By Body Part 15.3.5. By Indication 15.3.6. By End User 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Product 15.4.3. By Test Type 15.4.4. By Body Part 15.4.5. By Indication 15.4.6. By End User 15.5. Country Level Analysis & Forecast 15.5.1. USA Market Analysis 15.5.1.1. .Introduction 15.5.1.2. Market Analysis and Forecast by Market Taxonomy 15.5.1.2.1. By Product 15.5.1.2.2. By Test Type 15.5.1.2.3. By Body Part 15.5.1.2.4. By Indication 15.5.1.2.5. By End User 15.5.2. Canada Market Analysis 15.5.2.1. Introduction 15.5.2.2. Market Analysis and Forecast by Market Taxonomy 15.5.2.2.1. By Product 15.5.2.2.2. By Test Type 15.5.2.2.3. By Body Part 15.5.2.2.4. By Indication 15.5.2.2.5. By End User 15.6. Market Trends 15.7. Key Market Participants - Intensity Mapping 15.8. Drivers and Restraints - Impact Analysis 16. Latin America Market Analysis 2012 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2012 to 2022 16.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. Brazil 16.3.1.2. Mexico 16.3.1.3. Argentina 16.3.1.4. Rest of Latin America 16.3.2. By Product 16.3.3. By Test Type 16.3.4. By Body Part 16.3.5. By Indication 16.3.6. By End User 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Product 16.4.3. By Test Type 16.4.4. By Body Part 16.4.5. By Indication 16.4.6. By End User 16.5. Country Level Analysis & Forecast 16.5.1. Brazil Market Analysis 16.5.1.1. .Introduction 16.5.1.2. Market Analysis and Forecast by Market Taxonomy 16.5.1.2.1. By Product 16.5.1.2.2. By Test Type 16.5.1.2.3. By Body Part 16.5.1.2.4. By Indication 16.5.1.2.5. By End User 16.5.2. Mexico Market Analysis 16.5.2.1. Introduction 16.5.2.2. Market Analysis and Forecast by Market Taxonomy 16.5.2.2.1. By Product 16.5.2.2.2. By Test Type 16.5.2.2.3. By Body Part 16.5.2.2.4. By Indication 16.5.2.2.5. By End User 16.5.3. Argentina Market Analysis 16.5.3.1. Introduction 16.5.3.2. Market Analysis and Forecast by Market Taxonomy 16.5.3.2.1. By Product 16.5.3.2.2. By Test Type 16.5.3.2.3. By Body Part 16.5.3.2.4. By Indication 16.5.3.2.5. By End User 16.6. Market Trends 16.7. Key Market Participants - Intensity Mapping 16.8. Drivers and Restraints - Impact Analysis 17. Europe Market Analysis 2012 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2012 to 2022 17.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. Germany 17.3.1.2. France 17.3.1.3. Italy 17.3.1.4. UK 17.3.1.5. Spain 17.3.1.6. Russia 17.3.1.7. BENELUX 17.3.1.8. Rest of Europe 17.3.2. By Product 17.3.3. By Test Type 17.3.4. By Body Part 17.3.5. By Indication 17.3.6. By End User 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Product 17.4.3. By Test Type 17.4.4. By Body Part 17.4.5. By Indication 17.4.6. By End User 17.5. Country Level Analysis & Forecast 17.5.1. Germany Market Analysis 17.5.1.1. .Introduction 17.5.1.2. Market Analysis and Forecast by Market Taxonomy 17.5.1.2.1. By Product 17.5.1.2.2. By Test Type 17.5.1.2.3. By Body Part 17.5.1.2.4. By Indication 17.5.1.2.5. By End User 17.5.2. France Market Analysis 17.5.2.1. Introduction 17.5.2.2. Market Analysis and Forecast by Market Taxonomy 17.5.2.2.1. By Product 17.5.2.2.2. By Test Type 17.5.2.2.3. By Body Part 17.5.2.2.4. By Indication 17.5.2.2.5. By End User 17.5.3. Italy Market Analysis 17.5.3.1. Introduction 17.5.3.2. Market Analysis and Forecast by Market Taxonomy 17.5.3.2.1. By Product 17.5.3.2.2. By Test Type 17.5.3.2.3. By Body Part 17.5.3.2.4. By Indication 17.5.3.2.5. By End User 17.5.4. UK Market Analysis 17.5.4.1. .Introduction 17.5.4.2. Market Analysis and Forecast by Market Taxonomy 17.5.4.2.1. By Product 17.5.4.2.2. By Test Type 17.5.4.2.3. By Body Part 17.5.4.2.4. By Indication 17.5.4.2.5. By End User 17.5.5. Spain Market Analysis 17.5.5.1. .Introduction 17.5.5.2. Market Analysis and Forecast by Market Taxonomy 17.5.5.2.1. By Product 17.5.5.2.2. By Test Type 17.5.5.2.3. By Body Part 17.5.5.2.4. By Indication 17.5.5.2.5. By End User 17.5.6. Russia Market Analysis 17.5.6.1. .Introduction 17.5.6.2. Market Analysis and Forecast by Market Taxonomy 17.5.6.2.1. By Product 17.5.6.2.2. By Test Type 17.5.6.2.3. By Body Part 17.5.6.2.4. By Indication 17.5.6.2.5. By End User 17.5.7. BENELUX Market Analysis 17.5.7.1. .Introduction 17.5.7.2. Market Analysis and Forecast by Market Taxonomy 17.5.7.2.1. By Product 17.5.7.2.2. By Test Type 17.5.7.2.3. By Body Part 17.5.7.2.4. By Indication 17.5.7.2.5. By End User 17.6. Market Trends 17.7. Key Market Participants - Intensity Mapping 17.8. Drivers and Restraints - Impact Analysis 18. South Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2012 to 2022 18.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 18.3.1. By Country 18.3.1.1. India 18.3.1.2. Thailand 18.3.1.3. Indonesia 18.3.1.4. Malaysia 18.3.1.5. Rest of South Asia 18.3.2. By Product 18.3.3. By Test Type 18.3.4. By Body Part 18.3.5. By Indication 18.3.6. By End User 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Product 18.4.3. By Test Type 18.4.4. By Body Part 18.4.5. By Indication 18.4.6. By End User 18.5. Country Level Analysis & Forecast 18.5.1. India Market Analysis 18.5.1.1. .Introduction 18.5.1.2. Market Analysis and Forecast by Market Taxonomy 18.5.1.2.1. By Product 18.5.1.2.2. By Test Type 18.5.1.2.3. By Body Part 18.5.1.2.4. By Indication 18.5.1.2.5. By End User 18.5.2. Thailand Market Analysis 18.5.2.1. .Introduction 18.5.2.2. Market Analysis and Forecast by Market Taxonomy 18.5.2.2.1. By Product 18.5.2.2.2. By Test Type 18.5.2.2.3. By Body Part 18.5.2.2.4. By Indication 18.5.2.2.5. By End User 18.5.3. Indonesia Market Analysis 18.5.3.1. Introduction 18.5.3.2. Market Analysis and Forecast by Market Taxonomy 18.5.3.2.1. By Product 18.5.3.2.2. By Test Type 18.5.3.2.3. By Body Part 18.5.3.2.4. By Indication 18.5.3.2.5. By End User 18.5.4. Malaysia Market Analysis 18.5.4.1. Introduction 18.5.4.2. Market Analysis and Forecast by Market Taxonomy 18.5.4.2.1. By Product 18.5.4.2.2. By Test Type 18.5.4.2.3. By Body Part 18.5.4.2.4. By Indication 18.5.4.2.5. By End User 18.6. Market Trends 18.7. Key Market Participants - Intensity Mapping 18.8. Drivers and Restraints - Impact Analysis 19. East Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033 19.1. Introduction 19.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2012 to 2022 19.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 19.3.1. By Country 19.3.1.1. China 19.3.1.2. Japan 19.3.1.3. South Korea 19.3.2. By Product 19.3.3. By Test Type 19.3.4. By Body Part 19.3.5. By Indication 19.3.6. By End User 19.4. Market Attractiveness Analysis 19.4.1. By Country 19.4.2. By Product 19.4.3. By Test Type 19.4.4. By Body Part 19.4.5. By Indication 19.4.6. By End User 19.5. Country Level Analysis & Forecast 19.5.1. China Market Analysis 19.5.1.1. .Introduction 19.5.1.2. Market Analysis and Forecast by Market Taxonomy 19.5.1.2.1. By Product 19.5.1.2.2. By Test Type 19.5.1.2.3. By Body Part 19.5.1.2.4. By Indication 19.5.1.2.5. By End User 19.5.2. Japan Market Analysis 19.5.2.1. Introduction 19.5.2.2. Market Analysis and Forecast by Market Taxonomy 19.5.2.2.1. By Product 19.5.2.2.2. By Test Type 19.5.2.2.3. By Body Part 19.5.2.2.4. By Indication 19.5.2.2.5. By End User 19.5.3. South Korea Market Analysis 19.5.3.1. Introduction 19.5.3.2. Market Analysis and Forecast by Market Taxonomy 19.5.3.2.1. By Product 19.5.3.2.2. By Test Type 19.5.3.2.3. By Body Part 19.5.3.2.4. By Indication 19.5.3.2.5. By End User 19.6. Market Trends 19.7. Key Market Participants - Intensity Mapping 19.8. Drivers and Restraints - Impact Analysis 20. Oceania Market Analysis 2012 to 2022 and Forecast 2023 to 2033 20.1. Introduction 20.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2012 to 2022 20.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 20.3.1. By Country 20.3.1.1. Australia 20.3.1.2. New Zealand 20.3.2. By Product 20.3.3. By Test Type 20.3.4. By Body Part 20.3.5. By Indication 20.3.6. By End User 20.4. Market Attractiveness Analysis 20.4.1. By Country 20.4.2. By Product 20.4.3. By Test Type 20.4.4. By Body Part 20.4.5. By Indication 20.4.6. By End User 20.5. Country Level Analysis & Forecast 20.5.1. Australia Market Analysis 20.5.1.1. .Introduction 20.5.1.2. Market Analysis and Forecast by Market Taxonomy 20.5.1.2.1. By Product 20.5.1.2.2. By Test Type 20.5.1.2.3. By Body Part 20.5.1.2.4. By Indication 20.5.1.2.5. By End User 20.5.2. New Zealand Market Analysis 20.5.2.1. Introduction 20.5.2.2. Market Analysis and Forecast by Market Taxonomy 20.5.2.2.1. By Product 20.5.2.2.2. By Test Type 20.5.2.2.3. By Body Part 20.5.2.2.4. By Indication 20.5.2.2.5. By End User 20.6. Market Trends 20.7. Key Market Participants - Intensity Mapping 20.8. Drivers and Restraints - Impact Analysis 21. Middle East and Africa Market Analysis 2012 to 2022 and Forecast 2023 to 2033 21.1. Introduction 21.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2012 to 2022 21.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 21.3.1. By Country 21.3.1.1. GCC Countries 21.3.1.2. Türkiye 21.3.1.3. Northern Africa 21.3.1.4. South Africa 21.3.1.5. Rest of Middle East and Africa 21.3.2. By Product 21.3.3. By Test Type 21.3.4. By Body Part 21.3.5. By Indication 21.3.6. By End User 21.4. Market Attractiveness Analysis 21.4.1. By Country 21.4.2. By Product 21.4.3. By Test Type 21.4.4. By Body Part 21.4.5. By Indication 21.4.6. By End User 21.5. Country Level Analysis & Forecast 21.5.1. GCC Countries Market Analysis 21.5.1.1. .Introduction 21.5.1.2. Market Analysis and Forecast by Market Taxonomy 21.5.1.2.1. By Product 21.5.1.2.2. By Test Type 21.5.1.2.3. By Body Part 21.5.1.2.4. By Indication 21.5.1.2.5. By End User 21.5.2. Türkiye Market Analysis 21.5.2.1. Introduction 21.5.2.2. Market Analysis and Forecast by Market Taxonomy 21.5.2.2.1. By Product 21.5.2.2.2. By Test Type 21.5.2.2.3. By Body Part 21.5.2.2.4. By Indication 21.5.2.2.5. By End User 21.5.3. Northern Africa Market Analysis 21.5.3.1. Introduction 21.5.3.2. Market Analysis and Forecast by Market Taxonomy 21.5.3.2.1. By Product 21.5.3.2.2. By Test Type 21.5.3.2.3. By Body Part 21.5.3.2.4. By Indication 21.5.3.2.5. By End User 21.5.4. South Africa Market Analysis 21.5.4.1. Introduction 21.5.4.2. Market Analysis and Forecast by Market Taxonomy 21.5.4.2.1. By Product 21.5.4.2.2. By Test Type 21.5.4.2.3. By Body Part 21.5.4.2.4. By Indication 21.5.4.2.5. By End User 21.6. Market Trends 21.7. Key Market Participants - Intensity Mapping 21.8. Drivers and Restraints - Impact Analysis 22. Market Structure Analysis 22.1. Market Analysis by Tier of Companies 22.2. Market Share Analysis of Top Players 22.3. Market Presence Analysis 23. Competition Analysis 23.1. Competition Dashboard 23.2. Competition Benchmarking 23.3. Competition Deep Dive 23.3.1. Hologic Inc. 23.3.1.1. Overview 23.3.1.2. Product Portfolio 23.3.1.3. Key Financials 23.3.1.4. Sales Footprint 23.3.1.5. SWOT Analysis 23.3.1.6. Strategy Overview 23.3.1.6.1. Marketing Strategy 23.3.1.6.2. Product Strategy 23.3.1.6.3. Channel Strategy 23.3.2. Becton, Dickinson and Company 23.3.2.1. Overview 23.3.2.2. Product Portfolio 23.3.2.3. Key Financials 23.3.2.4. Sales Footprint 23.3.2.5. SWOT Analysis 23.3.2.6. Strategy Overview 23.3.2.6.1. Marketing Strategy 23.3.2.6.2. Product Strategy 23.3.2.6.3. Channel Strategy 23.3.3. Natureland Health 23.3.3.1. Overview 23.3.3.2. Product Portfolio 23.3.3.3. Key Financials 23.3.3.4. Sales Footprint 23.3.3.5. SWOT Analysis 23.3.3.6. Strategy Overview 23.3.3.6.1. Marketing Strategy 23.3.3.6.2. Product Strategy 23.3.3.6.3. Channel Strategy 23.3.4. Stix's 23.3.4.1. Overview 23.3.4.2. Product Portfolio 23.3.4.3. Key Financials 23.3.4.4. Sales Footprint 23.3.4.5. SWOT Analysis 23.3.4.6. Strategy Overview 23.3.4.6.1. Marketing Strategy 23.3.4.6.2. Product Strategy 23.3.4.6.3. Channel Strategy 23.3.5. PGYARD 23.3.5.1. Overview 23.3.5.2. Product Portfolio 23.3.5.3. Key Financials 23.3.5.4. Sales Footprint 23.3.5.5. SWOT Analysis 23.3.5.6. Strategy Overview 23.3.5.6.1. Marketing Strategy 23.3.5.6.2. Product Strategy 23.3.5.6.3. Channel Strategy 23.3.6. myLAB Box 23.3.6.1. Overview 23.3.6.2. Product Portfolio 23.3.6.3. Key Financials 23.3.6.4. Sales Footprint 23.3.6.5. SWOT Analysis 23.3.6.6. Strategy Overview 23.3.6.6.1. Marketing Strategy 23.3.6.6.2. Product Strategy 23.3.6.6.3. Channel Strategy 23.3.7. Juno Bio 23.3.7.1. Overview 23.3.7.2. Product Portfolio 23.3.7.3. Key Financials 23.3.7.4. Sales Footprint 23.3.7.5. SWOT Analysis 23.3.7.6. Strategy Overview 23.3.7.6.1. Marketing Strategy 23.3.7.6.2. Product Strategy 23.3.7.6.3. Channel Strategy 23.3.8. Seroflora 23.3.8.1. Overview 23.3.8.2. Product Portfolio 23.3.8.3. Key Financials 23.3.8.4. Sales Footprint 23.3.8.5. SWOT Analysis 23.3.8.6. Strategy Overview 23.3.8.6.1. Marketing Strategy 23.3.8.6.2. Product Strategy 23.3.8.6.3. Channel Strategy 23.3.9. PrivaPath Diagnostics 23.3.9.1. Overview 23.3.9.2. Product Portfolio 23.3.9.3. Key Financials 23.3.9.4. Sales Footprint 23.3.9.5. SWOT Analysis 23.3.9.6. Strategy Overview 23.3.9.6.1. Marketing Strategy 23.3.9.6.2. Product Strategy 23.3.9.6.3. Channel Strategy 23.3.10. NutraBlast 23.3.10.1. Overview 23.3.10.2. Product Portfolio 23.3.10.3. Key Financials 23.3.10.4. Sales Footprint 23.3.10.5. SWOT Analysis 23.3.10.6. Strategy Overview 23.3.10.6.1. Marketing Strategy 23.3.10.6.2. Product Strategy 23.3.10.6.3. Channel Strategy 23.3.11. Rite Aid Corporation 23.3.11.1. Overview 23.3.11.2. Product Portfolio 23.3.11.3. Key Financials 23.3.11.4. Sales Footprint 23.3.11.5. SWOT Analysis 23.3.11.6. Strategy Overview 23.3.11.6.1. Marketing Strategy 23.3.11.6.2. Product Strategy 23.3.11.6.3. Channel Strategy 23.3.12. Home Health (UK) Ltd 23.3.12.1. Overview 23.3.12.2. Product Portfolio 23.3.12.3. Key Financials 23.3.12.4. Sales Footprint 23.3.12.5. SWOT Analysis 23.3.12.6. Strategy Overview 23.3.12.6.1. Marketing Strategy 23.3.12.6.2. Product Strategy 23.3.12.6.3. Channel Strategy 23.3.13. Loyalbody 23.3.13.1. Overview 23.3.13.2. Product Portfolio 23.3.13.3. Key Financials 23.3.13.4. Sales Footprint 23.3.13.5. SWOT Analysis 23.3.13.6. Strategy Overview 23.3.13.6.1. Marketing Strategy 23.3.13.6.2. Product Strategy 23.3.13.6.3. Channel Strategy 23.3.14. Savyon Diagnostics 23.3.14.1. Overview 23.3.14.2. Product Portfolio 23.3.14.3. Key Financials 23.3.14.4. Sales Footprint 23.3.14.5. SWOT Analysis 23.3.14.6. Strategy Overview 23.3.14.6.1. Marketing Strategy 23.3.14.6.2. Product Strategy 23.3.14.6.3. Channel Strategy 23.3.15. BIOSYNEX SA 23.3.15.1. Overview 23.3.15.2. Product Portfolio 23.3.15.3. Key Financials 23.3.15.4. Sales Footprint 23.3.15.5. SWOT Analysis 23.3.15.6. Strategy Overview 23.3.15.6.1. Marketing Strategy 23.3.15.6.2. Product Strategy 23.3.15.6.3. Channel Strategy 23.3.16. Quantbiome, Inc. 23.3.16.1. Overview 23.3.16.2. Product Portfolio 23.3.16.3. Key Financials 23.3.16.4. Sales Footprint 23.3.16.5. SWOT Analysis 23.3.16.6. Strategy Overview 23.3.16.6.1. Marketing Strategy 23.3.16.6.2. Product Strategy 23.3.16.6.3. Channel Strategy 24. Assumptions and Acronyms Used 25. Research Methodology
Explore Healthcare Insights
View Reports
Yeast Infection Diagnostics Market
